Meeting
2023 ASCO Annual Meeting
Do HER2 low tumors have a distinct clinicopathologic phenotype?
Authors
Natália Polidorio
Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY
Natália Polidorio , Srinivasa Sevilimedu Veeravalli , Giacomo Montagna , Tiana Le , Monica Morrow
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Biologic Correlates
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 570)
DOI
10.1200/JCO.2023.41.16_suppl.570
Abstract #
570
Poster Bd #
400
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Artificial intelligence–powered tumor-infiltrating lymphocytes analyzer to reveal distinct immune landscapes in breast cancer by molecular subtype and HER2 score.
First Author: Seunghwan Shin
Poster
2021 ASCO Annual Meeting
Comparison of therapy benefit from standard anti-HER2 directed approaches in metastatic breast cancer (MBC) between initially HER2-positive patients and patients initially HER2-negative with switch to HER2-positive.
First Author: Hans-Christian Kolberg
Poster
2020 ASCO Virtual Scientific Program
Adding precision to 2018 ASCO/CAP HER2 testing guidelines in breast cancer with genomic profiling.
First Author: Adam Brufsky
Poster
2016 ASCO Annual Meeting
HER2 equivocal breast cancer and neoadjuvant therapy: Is response similar to HER2-positive or HER2-negative tumors?
First Author: Alessandra Landmann